Latest News and Press Releases

Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no...

IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...

More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms First participants dosed in single ascending dose and...

IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...

Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July Announced FDA...

Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal...

Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention Allows initiation of Phase 1 study to evaluate safety, pharmacokinetics, and dosing More...

Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients ...

IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...

Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for...